BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Australia/Melbourne
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20200404T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20201003T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20210403T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20211002T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20220402T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20221001T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210304T100000
DTEND;TZID=America/New_York:20210304T113000
DTSTAMP:20260403T200718
CREATED:20210223T151424Z
LAST-MODIFIED:20210223T151424Z
UID:5022-1614852000-1614857400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Learning from COVID-19 to tackle the silent pandemic of antibiotic resistance
DESCRIPTION:The COVID-19 pandemic has brought into sharp focus the impact of pandemics. The novel coronavirus has claimed more than a million lives\, trillions of dollars have been lost\, expenditures cut and international efforts to achieve the Sustainable Development Goals put in jeopardy. \nCOVID-19 has demonstrated pandemic preparedness requires a global coordinated effort\, and no country can do it alone. Strengthening our ability to fight the silent pandemic of drug-resistant infections must also ensure affordable access to vital health tools\, including new and improved treatments. This webinar will focus on how we can apply the lessons learned from COVID-19 to tackle drug resistance and ensure access to appropriate antibiotics. \nSpeakers:  \n\nManica Balasegaram\, GARDP\nJoanne Liu\, University of Montreal and Médecins Sans Frontières\nMarc Mendelson\, Groote Schuur Hospital\, University of Cape Town\n\nModerator: Claire Doole \nThe presentations will be followed by a Q&A session. \nClick here to learn more and register.
URL:https://carb-x.org/event/live-webinar-gardp-revive-learning-from-covid-19-to-tackle-the-silent-pandemic-of-antibiotic-resistance/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210312T110000
DTEND;TZID=America/New_York:20210312T130000
DTSTAMP:20260403T200718
CREATED:20201203T001344Z
LAST-MODIFIED:20210210T172607Z
UID:4678-1615546800-1615554000@carb-x.org
SUMMARY:BARDA AMR Vaccine Public Workshop: Vaccines against AMR Threats
DESCRIPTION:Multi-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis.  Every year\, 2.8 million American develop a drug resistant infection and 35\,000 people die. Globally\, MDR infections kill 700\,000 each year – current estimates are that MDR organisms will kill more than 10 million a year by 2050 if left unchecked. \nBARDA supports development and procurement of medical countermeasures to protect Americans against chemical\, biological\, radiological\, and nuclear (CBRN) threats. MDR does not discriminate\, and victims of CBRN events are at risk of suffering fatal complications from drug resistant infections. One of BARDA’s top priorities is to develop a vaccine to protect people from these threats. \nHelp BARDA fight AMR! Join the workshop to learn more about BARDA\, our mission\, and how we plan to tackle this growing threat. The event will consist of presentations from BARDA experts\, followed by a structured discussion\, and Q&A. Companies and others interested in working with BARDA are encouraged to attend the March 12\, 2021 workshop. The event is open to the public\, but space is limited. Be sure to register by March 5\, 2021. Please\, no more than four people from one organization. Are you a product developer working on a vaccine against one of the four targeted pathogens? Then we want to talk with you! Be sure to request a private meeting when you register for the workshop. \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/pandemic-prevention-and-innovation-summit-identifying-opportunities-for-investment-collaboration-in-ensuring-future-pandemic-preparedness/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210325
DTSTAMP:20260403T200718
CREATED:20201203T003554Z
LAST-MODIFIED:20201203T003554Z
UID:4682-1616457600-1616630399@carb-x.org
SUMMARY:3rd Bacteriophage Therapy Summit 2021
DESCRIPTION:The 3rd Bacteriophage Therapy Summit returns! With a new looking speaker line-up and never before seen content\, we are excited to continue to unite the community to progress fundamental bacteriophage research into clinically-significant products. \nThe overuse of antibiotics had led to the development of multi-resistant bacterial strains\, most notably ESKAPE pathogens\, rendering the use of antibiotics\, which in many scenarios are useless. However\, bacteriophages may hold the key in overcoming the global antibiotic resistance crisis. \nAlthough the potential use of phage and phage-derived products in a clinical setting is beginning to be understood\, there still remains a number of unique challenges associated with this novel therapeutic agent. A developing regulatory landscape\, up-scaling of manufacturing processes\, and the design of clinical trials are just a few of the roadblocks holding back development. \nBringing together leading drug developers\, academics and clinical researchers\, our agenda is focused to address the main translation challenges from characterization of phages through to clinical development. This is your opportunity to join your peers to strengthen your product development pipelines and forge new collaborations to unlock the full potential of bacteriophage therapeutics. \nCARB-X participants include Richard Alm\, Alliance Director. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/3rd-bacteriophage-therapy-summit-2021/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210327
DTSTAMP:20260403T200718
CREATED:20201203T004045Z
LAST-MODIFIED:20201203T004045Z
UID:4683-1616544000-1616803199@carb-x.org
SUMMARY:Australasian Society for Infectious Diseases (ASID) Annual Scientific Meeting
DESCRIPTION:The ASID Annual Scientific Meeting is the leading Australasian meeting for adult and paediatric infectious disease and clinical microbiology specialists. The conference is an ideal opportunity for connecting clinicians\, microbiologists and other health professions with a common interest in infectious diseases and provides a friendly forum for the exchange of scientific advances in the prevention\, diagnosis and management of clinical infectious diseases. International speakers will offer expert global perspectives on our themes and Australasian research and expertise will be highlighted with keynote lectures\, proffered papers and symposia. The main theme is “Hospital Infectious Diseases” \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/australasian-society-for-infectious-diseases-asid-annual-scientific-meeting/
LOCATION:Pullman Melbourne on the Park\, 192 Wellington Parade\, MELBOURNE\, 3002\, Australia
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210325T120000
DTEND;TZID=America/New_York:20210325T130000
DTSTAMP:20260403T200718
CREATED:20210317T172121Z
LAST-MODIFIED:20210317T172121Z
UID:5174-1616673600-1616677200@carb-x.org
SUMMARY:The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (Levy CIMAR) Monthly Science Meeting: Innovation Solutions to AMR
DESCRIPTION:Please join us on Thursday\, March 25th\, at noon for this month’s Levy CIMAR Science Meeting on “Innovation Solutions to AMR.” We are excited to hear from Kevin Outterson\, Esq.\, Professor of Law at Boston University and Executive Director of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator\, or CARB-X. CARB-X is a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics\, diagnostics\, and vaccines that tackle the threat of untreatable bacterial infections. \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more about Levy CIMAR.\nContact Rima Mycynek @ Rima.Mycynek@tufts.edu for Zoom Details.
URL:https://carb-x.org/event/the-stuart-b-levy-center-for-integrated-management-of-antimicrobial-resistance-at-tufts-levy-cimar-monthly-science-meeting-innovation-solutions-to-amr/
LOCATION:VIRTUAL EVENT
END:VEVENT
END:VCALENDAR